About Harrisvaccines
Harrisvaccines is a Healthcare company based in Ames (United States) founded in 2005, and was acquired by Merck Animal Health in November 2015. Developer of vaccine technology for the treatment of infectious diseases. It operates in the Healthcare and Agriculture sectors. Harrisvaccines has raised $5 million across 3 funding rounds from investors including Merck Animal Health, NIFA and United States Department of Agriculture. Harrisvaccines offers products and services including Vaccines, Medicines, and DNA TraceBack. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified. Its legal entity is Merck & Co., Inc. Its competitors include Avidity Biosciences, Sutro Biopharma and Antheia; 3 of its 3 listed competitors have raised funding.
Company details
Harrisvaccines uses RNA Particle (RP) technology to develop herd-specific vaccines. The technology developed by the company to develop the vaccine does not need the virus, instead, it needs only the data to determine the subtype or strain of a specific virus. The gene sequence of the virus is considered for developing the vaccine. Using its technology the company developed a vaccine called iPED in 2013 to fight Porcine Epidemic Diarrhea virus in an epidemic across Canada and North America. The company had also developed a Swine Influenza Vaccine, which was licensed for use as an aid in the prevention of disease caused by Swine Influenza, H3N2.
- Headquarters Ames, United States
- Stage Acquired
- SectorsHealthcareAgriculture
- Phoneβ’β’β’β’ β’β’β’β’
- Website harrisvaccines.com
- Social LinkedIn X Facebook Instagram YouTube
- Acquired by Merck Animal Health (Nov 2015)
- Legal Name Merck & Co., Inc.
- Total Equity Funding$5M (USD)
in 3 rounds
- InvestorsMerck Animal Health
& 2 more
- Acquired byMerck Animal Health
(Nov 2015)
Products & Services of Harrisvaccines
Harrisvaccines offers a comprehensive portfolio of products and services, including Vaccines, Medicines, and DNA TraceBack.
Vaccines for preventing diseases in companion and livestock animals
Medicines to treat animal health conditions and improve welfare
Technology for tracking and monitoring animal genetics and health
Funding Insights of Harrisvaccines
Harrisvaccines has successfully raised a total of $5M across 3 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $5M
- Total Rounds 3
- First Round $460,000
(Sep 2011)
- Investors Count 2
All 3 funding rounds of Harrisvaccines with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2013 | Grant | β | β | ||
| Oct 2011 | $5M | Series A | β | β | β |
| Sep 2011 | $460,000 | Grant | β | β |
3 investors in total: 3 institutional.
Investors in Harrisvaccines
Harrisvaccines has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Merck Animal Health, NIFA and United States Department of Agriculture.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| nifa.usda.gov | ||||
Vaccine technology is developed and supplied for livestock animals. | 1921 | merck-animal-health.com | Madison, United States | |
Leadership is provided on agriculture, food, and rural development matters. | usda.gov |
Investor details for Harrisvaccines
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Harrisvaccines
4 dated milestones of Harrisvaccines across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Harrisvaccines is founded.
- Funding First funding round of $460K.
- Funding Latest funding round, Grant,.
- Exit Acquired by Merck Animal Health.
Competitors of Harrisvaccines
Harrisvaccines has 3 listed competitors in our database, 3 of them funded. They include Avidity Biosciences, Sutro Biopharma and Antheia.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. |
Detailed competitors of Harrisvaccines
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Harrisvaccines (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Harrisvaccines
Harrisvaccines was founded in 2005 and raised its 1st funding round 6 years after it was founded.
Harrisvaccines is headquartered in Ames, United States. It is registered at Ames, Iowa, United States.
Harrisvaccines is a funded company, having raised a total of $5M across 3 funding rounds to date. The company's 1st funding round was a Grant of $460K, raised on Sep 2011.
Harrisvaccines uses RNA Particle (RP) technology to develop herd-specific vaccines. The technology developed by the company to develop the vaccine does not need the virus, instead, it needs only the data to determine the subtype or strain of a specific virus. The gene sequence of the virus is considered for developing the vaccine. Using its technology the company developed a vaccine called iPED in 2013 to fight Porcine Epidemic Diarrhea virus in an epidemic across Canada and North America. The company had also developed a Swine Influenza Vaccine, which was licensed for use as an aid in the prevention of disease caused by Swine Influenza, H3N2.
Harrisvaccines's top competitors include Sutro Biopharma, Avidity Biosciences and Antheia.
Harrisvaccines offers Vaccines, Medicines, and DNA TraceBack.
Harrisvaccines has 3 investors. Key investors include Merck Animal Health, NIFA, and United States Department of Agriculture.
Harrisvaccines operates through Merck & Co., Inc..
Yes. Harrisvaccines was acquired by Merck Animal Health in November 2015.
